TheMHRA has advised that an application for a marketing authorisation for lenalidomidefor the treatment of multiple myeloma is pending with the EMEA.When a medicine receives a UKmarketing authorisation, either from the MHRA or the EMEA, it can be prescribedon the NHS unless it is subject to a direction by Scottish ministers under section17N(6) of the NHS (Scotland) Act 1978.However, NHS Scotland is expectedto await the advice of the Scottish Medicines Consortium (SMC) before making a newmedicine routinely available. SMC conducts rapid...